Dark

Check out our Dark Pool Levels

ALVR
AlloVir, Inc. Common Stock
stock NASDAQ

Inactive

Mar 18, 2025

9.81USD+1.553%(+0.15)9,429

Pre-market

0.00USD-100.000%(-9.66)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 18, 2022

08:52AM EST Morgan Stanley Maintains Overweight on AlloVir, Lowers Price Target to $45 Benzinga

Jan 5, 2022

07:38AM EST FDA Grants Regenerative Medicine Advanced Therapy Designation To AlloVir's Posoleucel For The Treatment Of Adenovirus Infections In Adults And Children Post-Allogeneic Stem Cell Transplantation Benzinga

Dec 17, 2021

07:54AM EST The Daily Biotech Pulse: Genfit Spikes On Liver Disease Drug Licensing Deal, Lyell Gets Nod For Solid Tumor Study, Decision-Day For Intra-Cellular, Argenx Benzinga

04:42AM EST SVB Leerink Maintains Outperform on AlloVir, Lowers Price Target to $32 Benzinga

Dec 13, 2021

12:38PM EST AlloVir Saturday Announced Prelim. Data From Ongoing Phase 2 Posoleucel Multi-Virus Prevention Study At American Society Of Hematology Meeting Benzinga

Dec 6, 2021

06:07AM EST The Week Ahead In Biotech (Dec. 6-Dec. 11): Dar FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More Benzinga

Nov 8, 2021

03:53AM EST SVB Leerink Maintains Outperform on AlloVir, Lowers Price Target to $37 Benzinga

Nov 5, 2021

09:39AM EDT AlloVir Q3 EPS $(0.72) Down From $(0.58) YoY Benzinga

Oct 12, 2021

08:01AM EDT Morgan Stanley Maintains Overweight on AlloVir, Raises Price Target to $48 Benzinga

Oct 4, 2021

07:05AM EDT AlloVir Announces The FDA Has Granted Orphan Drug Designation To The Co.'s Posoleucel, An Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell Therapy, For The Treatment Of Virus-Associated Hemorrhagic Cystitis Benzinga

Sep 29, 2021

01:48PM EDT AlloVir Earlier Granted FDA Orpha Drug Status For 'Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpes virus-6, Epstein Barr virus, and adenovirus' Benzinga

07:59AM EDT Morgan Stanley Maintains Overweight on AlloVir, Raises Price Target to $225 Benzinga

07:13AM EDT AlloVir Highlights Publication Of ALVR109 Data At IDWeek Benzinga

Sep 7, 2021

07:00AM EDT AlloVir to Present at the Morgan Stanley 19th Annual Global Healthcare Conference Business Wire

Aug 18, 2021

07:36AM EDT Morgan Stanley Maintains Overweight on AlloVir, Lowers Price Target to $47 Benzinga

Aug 6, 2021

08:21AM EDT CORRECTION: AlloVir Ticker Is 'ALVR' Benzinga

08:20AM EDT AlloVir Files For Mixed Shelf Offering; Size Not Disclosed Benzinga

07:06AM EDT AlloVir Q2 EPS $(0.60) Up From $(4.43) YoY Benzinga

Jul 16, 2021

07:37AM EDT The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study Benzinga

Jul 15, 2021

08:08AM EDT The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs Benzinga

Jul 9, 2021

07:36AM EDT The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO Benzinga

May 11, 2021

07:54AM EDT The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings Benzinga

May 6, 2021

12:12PM EDT SVB Leerink Maintains Outperform on AlloVir, Raises Price Target to $42 Benzinga

08:01AM EDT AlloVir Q1 2021 EPS $(0.50) Vs $(4.21) YoY Benzinga

Apr 19, 2021

10:24AM EDT AlloVir shares were trading higher after Morgan Stanley maintained its Overweight rating on the stock and raised its price target of $49 to $50 per share. Benzinga

09:13AM EDT Morgan Stanley Maintains Overweight on AlloVir, Raises Price Target to $50 Benzinga

Mar 23, 2021

08:18AM EDT The Daily Biotech Pulse: FDA Approvals For Merck, Pacira And Zealand, Roche-Regeneron Ace Late-Stage COVID-19 Study, AlloVir Appoints Gilead Virology Chief As CEO Benzinga

Mar 22, 2021

04:01PM EDT AlloVir Appoints Diana M. Brainard, M.D., As Chief Executive Officer Benzinga

Dec 23, 2020

08:31AM EST The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut Benzinga

Dec 17, 2020

07:31AM EST AlloVir Announces FDA Clearance of Investigational New Drug Application for ALVR106, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T Cell Therapy Targeting Four Devastating Respiratory Viruses Benzinga

Dec 10, 2020

01:03PM EST Company Profile for AlloVir Business Wire

Dec 8, 2020

08:04AM EST The Daily Biotech Pulse: ASH Presentations, Axsome's Positive Midstage Readout, Follow-On Offerings Benzinga

Dec 7, 2020

04:31PM EST AlloVir Reports Phase 2 Proof-Of-Concept Data For Viralym-M, Burden Of Disease Data Presented At American Society Of Hematology Meeting Benzinga

Dec 6, 2020

08:41AM EST Week Ahead In Biotech: FDA To Decide On Emergency Use Of Pfizer's COVID Vaccine, Hematology Conference Presentations Pick Up Pace Benzinga

Nov 24, 2020

07:30AM EST AlloVir to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference Business Wire

Nov 10, 2020

07:00AM EST - Completed initial public offering raising $317.7M in gross proceeds GlobeNewswire Inc

Nov 4, 2020

01:33PM EST AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced that it will present three abstracts as oral presentations that support its pipeline of allogeneic, off-the-shelf virus-specific T cell therapies during the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition taking place virtually December 5 8, 2020. GlobeNewswire Inc

Oct 21, 2020

07:30AM EDT Data to Be Presented at IDWeek 2020 Demonstrate GlobeNewswire Inc

Sep 17, 2020

10:06AM EDT AlloVir Announces FDA Clearance of Investigational New Drug Application For ALVR109 For Treatment Of High-Risk Coronavirus Patients; Proof-Of-Concept Clinical Trial To Begin Q4 2020 Benzinga

09:50AM EDT - ALVR109 is an allogeneic, off-the-shelf virus-specific T cell therapy candidate designed to target SARS-CoV-2 for high-risk COVID-19 patients GlobeNewswire Inc

Sep 8, 2020

04:15PM EDT AlloVir Appoints Ercem Atillasoy, M.D., as Chief Regulatory and GlobeNewswire Inc

Sep 2, 2020

07:39AM EDT AlloVir Q2 Net Loss $11.6 Mln Or $4.43/Shr Vs Loss $5.3 Mln Or $5.05/Shr Last Year RTTNews

07:37AM EDT AlloVir Q2 EPS $(4.43) Up From $(5.05) YoY Benzinga

07:30AM EDT AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today reported financial results for the second quarter ended June 30, 2020. GlobeNewswire Inc

Aug 25, 2020

07:30AM EDT AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the virtual Morgan Stanley 18th Annual Global Healthcare Conference on September 17, 2020 at 5:00 p.m. ET. GlobeNewswire Inc

Aug 24, 2020

11:55AM EDT JP Morgan Initiates Coverage On AlloVir with Overweight Rating, Announces Price Target of $50 Benzinga

09:34AM EDT Benzinga's Top Upgrades, Downgrades For August 24, 2020 Benzinga

07:37AM EDT Morgan Stanley Initiates Coverage On AlloVir with Overweight Rating, Announces Price Target of $49 Benzinga

06:43AM EDT SVB Leerink Initiates Coverage On AlloVir with Outperform Rating, Announces Price Target of $41 Benzinga

Aug 8, 2020

04:03PM EDT Notable Insider Buys at Allovir, Xerox And Many More Benzinga

Aug 6, 2020

07:57AM EDT The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO Benzinga

07:19AM EDT Biocryst Pharmaceuticals Q2 EPS $(0.24) Beats $(0.25) Estimate Benzinga

Aug 3, 2020

04:30PM EDT AlloVir Announces Closing of Upsized Initial Public Offering and GlobeNewswire Inc

Jul 30, 2020

11:03AM EDT AlloVir Shares Open For Trade At $20; IPO Priced At $17/Share Benzinga

09:44AM EDT AlloVir Shares Expected To Open For Quote At 10:10 a.m. EDT, Expected To Open For Trade At 10:20 a.m. EDT; IPO Priced At $17/Share Benzinga

07:52AM EDT AlloVir Announces Pricing Of Upsized Initial Public Offering Of 16.25M At $17/Share Benzinga

07:33AM EDT AlloVir Announces Pricing of Upsized Initial Public Offering GlobeNewswire Inc

Share